International journal of radiation oncology, biology, physics · 2025
Low Dose-Averaged Linear Energy Transfer Contributes to Local Recurrence of Pancreatic Cancer Treated With Carbon Ion Radiation Therapy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sakamoto Soichiro, Oike Takahiro, Kobayashi Daijiro, Miyasaka Yuhei, Sakai Makoto, Okamoto Masahiko, Shiba Shintaro, Tomizawa Kento, Darwis Narisa Dewi Maulany, Yoshida Hanae, Tashiro Mutsumi, Ohno Tatsuya
Аннотация
PURPOSE: To evaluate the effects of dose-averaged linear energy transfer (LETd) profiles on local control (LC) of pancreatic cancer treated with carbon ion radiation therapy (CIRT).
METHODS AND MATERIALS: Data from patients with inoperable pancreatic cancer, treated with CIRT and concurrent chemotherapy between 2013 and 2021, were analyzed retrospectively. The prescribed dose was 55.2 Gy (relative biological effectiveness), administered in 12 fractions. The LETd of CIRT plans were calculated using a previously reported in-house pipeline. The association between tumor LETd profiles and local recurrence (LR) was analyzed.
RESULTS: The study analyzed 106 patients. The 2-year cumulative LR rate was 20.2% (95% confidence interval [CI], 12.8%-28.9%). Analysis of LETd parameters using a Fine-Gray regression model showed that the minimum LETd (Lmin) for the clinical target volume (CTV) had a significant effect on LR (P = .023). According to the cut-off value of 42.2 keV/µm, determined by time-dependent receiver operating characteristic analysis at 18 months, patients with low CTV Lmin had a significantly greater cumulative LR rate than those with high CTV Lmin (P = .020; 2-year cumulative LR rate, 32.4% [95% CI, 16.6%-49.3%] vs 12.7% [95% CI, 5.8%-22.5%]). Cause-specific proportional hazards models identified CTV Lmin as a significant predictor of LR (hazard ratio, 0.83; [95% CI, 0.71-0.98]; P = .030). CTV Lmin showed a strong, significant negative correlation with CTV (P < .0001, r = -0.52).
CONCLUSIONS: This is the largest study investigating the association between tumor LETd profiles and LC post-CIRT. The results suggest that low LETd within the CTV is associated with poor LC in patients with pancreatic cancer treated with CIRT.
METHODS AND MATERIALS: Data from patients with inoperable pancreatic cancer, treated with CIRT and concurrent chemotherapy between 2013 and 2021, were analyzed retrospectively. The prescribed dose was 55.2 Gy (relative biological effectiveness), administered in 12 fractions. The LETd of CIRT plans were calculated using a previously reported in-house pipeline. The association between tumor LETd profiles and local recurrence (LR) was analyzed.
RESULTS: The study analyzed 106 patients. The 2-year cumulative LR rate was 20.2% (95% confidence interval [CI], 12.8%-28.9%). Analysis of LETd parameters using a Fine-Gray regression model showed that the minimum LETd (Lmin) for the clinical target volume (CTV) had a significant effect on LR (P = .023). According to the cut-off value of 42.2 keV/µm, determined by time-dependent receiver operating characteristic analysis at 18 months, patients with low CTV Lmin had a significantly greater cumulative LR rate than those with high CTV Lmin (P = .020; 2-year cumulative LR rate, 32.4% [95% CI, 16.6%-49.3%] vs 12.7% [95% CI, 5.8%-22.5%]). Cause-specific proportional hazards models identified CTV Lmin as a significant predictor of LR (hazard ratio, 0.83; [95% CI, 0.71-0.98]; P = .030). CTV Lmin showed a strong, significant negative correlation with CTV (P < .0001, r = -0.52).
CONCLUSIONS: This is the largest study investigating the association between tumor LETd profiles and LC post-CIRT. The results suggest that low LETd within the CTV is associated with poor LC in patients with pancreatic cancer treated with CIRT.